{"name":"Institut Paoli-Calmettes","slug":"institut-paoli-calmettes","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Vinorelbine, Cyclophosphamide and Interferon alpha 2b","genericName":"Vinorelbine, Cyclophosphamide and Interferon alpha 2b","slug":"vinorelbine-cyclophosphamide-and-interferon-alpha-2b","indication":"Other","status":"phase_1"},{"name":"immune-checkpoint inhibitors therapies","genericName":"immune-checkpoint inhibitors therapies","slug":"immune-checkpoint-inhibitors-therapies","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Vinorelbine, Cyclophosphamide and Interferon alpha 2b","genericName":"Vinorelbine, Cyclophosphamide and Interferon alpha 2b","slug":"vinorelbine-cyclophosphamide-and-interferon-alpha-2b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"immune-checkpoint inhibitors therapies","genericName":"immune-checkpoint inhibitors therapies","slug":"immune-checkpoint-inhibitors-therapies","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNNklBMjYySGE5UXRJTmpMWHBjMmVwMzRleVVndWlKMWpOZ2ozV3ozV1puOFFWVzlFSWZ5ek1XVHB2RHdqdFg3b0VMOW9HamhiS3BqaHNRRERzQjZFQ1ZFQnpteXprU0l1YU04THgtTFpxUmx4b1h6dVdiRWtMRU45Yk1CYThPS2gxcjRaRjh0LWFST05GU2ExanJrRWx1aExPOGNwaEMzdEVqdXo1STJxMm42SFpwZXVoS0o5NVNIYzRIb2dOVmtINTBtUmtiMVFq?oc=5","date":"2025-11-12","type":"earnings","source":"Business Wire","summary":"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Business Wire","headline":"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZHQ2Nl95N2hfa1BSSkNYbHRueWFxUkE2aER2Zzc5aElkbmhQNExVbmUwV3BnaDdwR1BQanhVUlhianctaTdKY2ZlNng1Z3ZNaGh4bWNxY1R5bEFhT2NYaW82RklycF92cTlPTWhoektiRVlabkd2bUViQ0UtSkhYMU1pbWN5QmFJMHVHaFI5b3BoMWlRUlJKR1ZtS0Q2bWNDbm9ZMXg3dUI?oc=5","date":"2025-11-12","type":"pipeline","source":"The Pharma Letter","summary":"Sophia Genetics collabs combine AI analytics with sequencing - The Pharma Letter","headline":"Sophia Genetics collabs combine AI analytics with sequencing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOa29EeGtaLTR3Ymlld2FjdVl5QmtpeDZyRVM4T1FYQnFUbGFMd2xKMWFocldabHZySTE5T0ozUmsweVhZWlhsM25MaTRwSy1oLUt6bVpuM0tUSXRjWjMtU2pmbnRNQUNIUzc1Z0pDT2hieWE5cUdXLTBJWXBDdG94TjRmOC1wZWo5NnlfRDZ4NVk5ZTNzS2pLYW5rQ0ZHcmgyR1pHeUVFa1NaYUdxM2FLT0Etak5VbkFLdXd3RnRnblNrbjRWTHFCaTJkZ0Rvd3ltQzhfZzYtZHMwMGE3UldNUVoyYkVfTXRWckhlWVBxc2RhemEyWlZ6VHFGbEZVZw?oc=5","date":"2024-10-21","type":"pipeline","source":"PR Newswire","summary":"Okomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target Validation - PR Newswire","headline":"Okomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target Validation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNbnFrNU1VTWlUdS02emphXzRqVzRWLWVDVnZoTEZTMFRjR0tkaU1JTmJyZWNuUnN1WHRnaVRSRmkzMW85NF9lTkdrcWxtdkxuUEZwbTI4TzVjWC1nWVdLMzR6UkF4WXA4Zm9jclNBVGYwR0NZT3hhdHZCVHB1RjdzZ0xPa19pNkhKN3l1NE8tMTZ0ZVBvV3d0TkNhRlppcHpfdTdDS1ZRTWdRcGh3REVCc0dhUWFFWEFfUUdRblBmNnYtLXdl?oc=5","date":"2022-08-15","type":"pipeline","source":"European Medical Journal","summary":"Improvements in Prostate Cancer Management: Focus on Imaging and Treatment - European Medical Journal","headline":"Improvements in Prostate Cancer Management: Focus on Imaging and Treatment","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"marketed":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}